PDF herunterladen
Semin Respir Crit Care Med 2009; 30(2): 179-188
DOI: 10.1055/s-0029-1202937
© Thieme Medical Publishers

Community-Acquired Pneumonia: The U.S. Perspective

Michael S. Niederman1 , 2
  • 1Division of Pulmonary Medicine and Critical Care Medicine, Department of Medicine, Winthrop University Hospital, Mineola, New York
  • 2Department of Medicine, SUNY at Stony Brook, Stony Brook, New York
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. März 2009 (online)

    Lizenzen und Reprints

ABSTRACT

Community-acquired pneumonia (CAP) is a common and serious problem in the United States, and the sixth leading cause of death in those over age 65. Not only has short-term mortality been evaluated, but 1-year mortality may be as high as 40% in Medicare patients who have been admitted to the hospital with CAP. In the United States, guidelines for CAP management have been available since 1993, with the most recent version published in 2007 as a joint effort of the Infectious Diseases Society of America and the American Thoracic Society. The current U.S. guidelines take into consideration unique bacteriologic patterns in the United States, particularly focusing on the role of drug-resistant pneumococcus, atypical pathogens, and methicillin-resistant Staphylococcus aureus, which explains why U.S. recommendations for therapy differ from those in Europe and the United Kingdom. Notable differences in the U.S. approach to CAP compared with elsewhere include not only a unique set of bacteriologic considerations and therapy recommendations that follow these concerns but also a different approach to assessing severity of illness and recommended diagnostic testing, as well as the inclusion of performance measures to optimize disease management. Compared with European and British guidelines, the U.S. therapy of CAP has a greater emphasis on the role of atypical pathogens, a more defined role for fluoroquinolones as first-line therapy, less reliance on oral therapy for hospitalized patients, and less regard for the value of certain β-lactam agents.

KEYWORDS

Pneumonia - drug-resistance - Streptococcus pneumoniae - Staphylococcus aureus - performance measures - guidelines - prognostic scoring - diagnostic testing

REFERENCES

  • 1 Mandell L A, Wunderink R G, Anzueto A et al.. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.  Clin Infect Dis. 2007;  44 S27-S72
    CrossrefPubMedSuche in Google Scholar
  • 2 American Thoracic Society .Trends in pneumonia and influenza morbidity and mortality. 2007 American Lung Association website http://www.lungusa.org/site/data and statistics
    Suche in Google Scholar
  • 3 Niederman M S, McCombs J S, Unger A N, Kumar A, Popovian R. The cost of treating community-acquired pneumonia.  Clin Ther. 1998;  20 820-837
    CrossrefPubMedSuche in Google Scholar
  • 4 Niederman M S, Brito V. Pneumonia in the older patient.  Clin Chest Med. 2007;  28 751-771
    CrossrefPubMedSuche in Google Scholar
  • 5 Fine M J, Smith M A, Carson C A et al.. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis.  JAMA. 1996;  275 134-141
    CrossrefPubMedSuche in Google Scholar
  • 6 Marston B J, Plouffe J F, File Jr T M et al.. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.  Arch Intern Med. 1997;  157 1709-1718
    CrossrefPubMedSuche in Google Scholar
  • 7 Kaplan V, Clermont G, Griffin M F et al.. Pneumonia: still the old man's friend?.  Arch Intern Med. 2003;  163 317-323
    CrossrefPubMedSuche in Google Scholar
  • 8 Lieberman D, Schlaeffer F, Boldur I et al.. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients.  Thorax. 1996;  51 179-184
    CrossrefPubMedSuche in Google Scholar
  • 9 Marrie T J, Peeling R W, Fine M J, Singer D E, Coley C M, Kapoor W N. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course.  Am J Med. 1996;  101 508-515
    CrossrefPubMedSuche in Google Scholar
  • 10 Ruiz M, Ewig S, Torres A et al.. Severe community-acquired pneumonia: risk factors and follow-up epidemiology.  Am J Respir Crit Care Med. 1999;  160 923-929
    PubMedSuche in Google Scholar
  • 11 Gleason P P, Meehan T P, Fine J M, Galusha D H, Fine M J. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.  Arch Intern Med. 1999;  159 2562-2572
    CrossrefPubMedSuche in Google Scholar
  • 12 Brown R B, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims made database.  Chest. 2003;  123 1503-1511
    CrossrefPubMedSuche in Google Scholar
  • 13 Weiss K, Tillotson G S. The controversy of combination vs. monotherapy in the treatment of hospitalized community-acquired pneumonia.  Chest. 2005;  128 940-946
    CrossrefPubMedSuche in Google Scholar
  • 14 Waterer G W, Somes G W, Wunderink R G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.  Arch Intern Med. 2001;  161 1837-1842
    CrossrefPubMedSuche in Google Scholar
  • 15 Mufson M A, Sanek R J. Bacteremic pneumococcal pneumonia in one American city: a 20 year longitudinal study, 1978–1997.  Am J Med. 1999;  107 34S-43S
    PubMedSuche in Google Scholar
  • 16 Baddour L M, Yu V L, Klugman K P et al.. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.  Am J Respir Crit Care Med. 2004;  170 440-444
    CrossrefPubMedSuche in Google Scholar
  • 17 Houck P M, MacLehose R F, Niederman M S, Lowery J K. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 Western states: 1993,1995,1997.  Chest. 2001;  119 1420-1426
    CrossrefPubMedSuche in Google Scholar
  • 18 British Thoracic Society . Guidelines for the management of community-acquired pneumonia in adults.  Thorax. 2001;  56(Suppl) 1-64
    CrossrefPubMedSuche in Google Scholar
  • 19 Feikin D R, Schuchat A, Kolczak M et al.. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997.  Am J Public Health. 2000;  90 223-229
    CrossrefPubMedSuche in Google Scholar
  • 20 Farrell D J, Felmingham D. The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae .  J Antimicrob Chemother. 2005;  56 795-797
    CrossrefPubMedSuche in Google Scholar
  • 21 Clinical and Laboratory Standards Institute .Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100–S18. Wayne, PA; Clinical and Laboratory Standards Institute 2008 http://Available at www.clsi.org
    Suche in Google Scholar
  • 22 Plouffe J F, Breiman R F, Facklam R R. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. Franklin County Pneumonia Study Group.  JAMA. 1996;  275 194-198
    CrossrefPubMedSuche in Google Scholar
  • 23 Metlay J P, Hofmann J, Cetron M S et al.. Impact of penicillin susceptibility on medical outcomes for adult patients with pneumococcal pneumonia.  Clin Infect Dis. 2000;  30 520-528
    CrossrefPubMedSuche in Google Scholar
  • 24 Turett G S, Blum S, Fazal B A, Justman J E, Telzak E E. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence.  Clin Infect Dis. 1999;  29 321-327
    CrossrefPubMedSuche in Google Scholar
  • 25 Moroney J F, Fiore A E, Harrison L H et al.. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance.  Clin Infect Dis. 2001;  32 797-805
    PubMedSuche in Google Scholar
  • 26 Daneman N, McGeer A, Low D E. Toronto Bacterial Diseases Network . Macrolide resistance in bacteremic pneumococcal disease: implications for patient management.  Clin Infect Dis. 2006;  43 432-438
    CrossrefPubMedSuche in Google Scholar
  • 27 Feldman R B, Rhew D C, Wong J Y, Charles R A, Goetz M B. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2 year experience from a veterans hospital.  Arch Intern Med. 2003;  163 1718-1726
    CrossrefPubMedSuche in Google Scholar
  • 28 Vanderkooi O G, Low D E, Green K et al.. Predicting antimicrobial resistance in invasive pneumococcal infections.  Clin Infect Dis. 2005;  40 1288-1297
    CrossrefPubMedSuche in Google Scholar
  • 29 Martinez J A, Horcajada J P, Almela M et al.. Addition of a macrolide to a B-lactam–based empirical antibiotic regimen is associated with lower in-patient mortality for patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2003;  36 389-395
    CrossrefPubMedSuche in Google Scholar
  • 30 Micek S T, Dunne M, Kollef M H. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production.  Chest. 2005;  128 2732-2738
    CrossrefPubMedSuche in Google Scholar
  • 31 Fine M J, Auble T E, Yealy D M et al.. A prediction rule to identify low-risk patients with community-acquired pneumonia.  N Engl J Med. 1997;  336 243-250
    CrossrefPubMedSuche in Google Scholar
  • 32 Lim W S, van der Erden M M, Laing R et al.. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.  Thorax. 2003;  58 377-382
    CrossrefPubMedSuche in Google Scholar
  • 33 Niederman M S, Feldman C, Richards G A. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds.  Eur Respir J. 2006;  27 9-11
    CrossrefPubMedSuche in Google Scholar
  • 34 Aujesky D, Auble T E, Yealy D M et al.. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia.  Am J Med. 2005;  118 384-392
    CrossrefPubMedSuche in Google Scholar
  • 35 Woodhead M, Blasi F, Ewig S et al.. Guidelines for the management of adult lower respiratory tract infections.  Eur Respir J. 2005;  26 1138-1180
    CrossrefPubMedSuche in Google Scholar
  • 36 Metersky M L, Ma A, Bratzler D W, Houck P M. Predicting bacteremia in patients with community-acquired pneumonia.  Am J Respir Crit Care Med. 2004;  169 342-347
    CrossrefPubMedSuche in Google Scholar
  • 37 File Jr T M, Garau J, Blasi F et al.. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.  Chest. 2004;  125 1888-1901
    CrossrefPubMedSuche in Google Scholar
  • 38 Leroy O, Saux P, Bedos J P, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors.  Chest. 2005;  128 172-183
    CrossrefPubMedSuche in Google Scholar
  • 39 Lodise T P, Kwa A, Cosler L, Gupta R, Smith R P. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.  Antimicrob Agents Chemother. 2007;  51 3977-3982
    CrossrefPubMedSuche in Google Scholar
  • 40 Houck P M, Bratzler D W, Nsa W, Ma A, Bartlett J G. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.  Arch Intern Med. 2004;  164 637-644
    CrossrefPubMedSuche in Google Scholar
  • 41 Wachter R M, Flanders S A, Fee C, Pronovost P J. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure.  Ann Intern Med. 2008;  149 29-32
    CrossrefPubMedSuche in Google Scholar
  • 42 Welker J A, Huston M, McCue J D. Antibiotic timing and errors in diagnosing pneumonia.  Arch Intern Med. 2008;  168 351-356
    CrossrefPubMedSuche in Google Scholar
  • 43 Polgreen P M, Chen Y Y, Cavanaugh J E. An outbreak of severe Clostridium difficile–associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia.  Infect Control Hosp Epidemiol. 2007;  28 212-214
    CrossrefPubMedSuche in Google Scholar
  • 44 Whitney C G, Farley M M, Hadler J et al.. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.  N Engl J Med. 2003;  348 1737-1764
    CrossrefPubMedSuche in Google Scholar
  • 45 Bender J M, Ampofo K, Korgenski K et al.. Pneumococcal necrotizing pneumonia in Utah: does serotype matter?.  Clin Infect Dis. 2008;  46 1346-1352
    CrossrefPubMedSuche in Google Scholar

Michael S NiedermanM.D. 

Division of Pulmonary Medicine and Critical Care Medicine, Department of Medicine, Winthrop University Hospital

222 Station Plaza N., Ste. 509, Mineola, NY 11501

eMail: mniederman@winthrop.org